RxDoctor Payments Data

Taylor Hoover

Family · Parkersburg, WVNPI 1841046596

Payments from drug & device makers

$1,364in general payments, 2019–2025

Across 50 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$307
  • AstraZeneca$203
  • Pfizer$184
  • Bayer$177
  • Novartis$155
  • Novo Nordisk$125
  • plus $213 from 8 others

What the payments were for

  • Food & beverage$1,364100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,364 in reported general payments places this provider in the 70th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$26,680
Medicare patients
136
Services billed
458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$27,073
EliquisApixaban25$17,541
EntrestoSacubitril/Valsartan19$17,251
Amiodarone Hcl17$688
Spironolactone78$492
Metoprolol Succinate38$353
Losartan Potassium31$276
Potassium Chloride12$242
Nitroglycerin21$199
Furosemide41$165
Hydralazine Hcl14$128
Isosorbide Mononitrate ErIsosorbide Mononitrate13$125
Metoprolol Tartrate15$115
Atorvastatin Calcium11$101
Carvedilol17$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$307$27,07323 claims
PfizerEliquis$184$17,54125 claims
NovartisEntresto$155$17,25119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,507 family providers in West Virginia.

Other family in Parkersburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →